Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients with Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic
| Autor: | Adrian Scutelnic, Mayte Sánchez van Kammen, Saskia Middeldorp, Jukka Putaala, Sini Hiltunen, Miguel A Barboza, Diana Aguiar de Sousa, Suzanne Silvis, Verena Schroeder, Erik Lindgren, Marcel Arnold, Marcel Levi, Johanna A. Kremer Hovinga, José M. Ferro, Turgut Tatlisumak, Katarina Jood, Antonio Arauz, Urs Fischer, Susanna M. Zuurbier, Thalia S. Field, Mirjam Rachel Heldner, Maryam Mansour, Justine Brodard, Jonathan M. Coutinho |
|---|---|
| Přispěvatelé: | HUS Neurocenter, University of Helsinki, Neurologian yksikkö, Department of Neurosciences, Graduate School, Neurology, ANS - Neurovascular Disorders, Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, ARD - Amsterdam Reproduction and Development, ACS - Atherosclerosis & ischemic syndromes |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty COVID-19 Vaccines Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] Platelet Factor 4 DIAGNOSIS 01 natural sciences Gastroenterology Antibodies 03 medical and health sciences Sinus Thrombosis Intracranial 0302 clinical medicine Interquartile range Internal medicine medicine Humans Platelet 030212 general & internal medicine 0101 mathematics Cerebral venous sinus thrombosis 610 Medicine & health Retrospective Studies Original Investigation biology business.industry Heparin 010102 general mathematics Retrospective cohort study General Medicine Middle Aged medicine.disease Thrombocytopenia 3. Good health 3121 General medicine internal medicine and other clinical medicine biology.protein Female Fresh frozen plasma Antibody business Platelet factor 4 medicine.drug |
| Zdroj: | JAMA, 326(4), 332-338. American Medical Association JAMA Jama : Journal of the American Medical Association, 326, 4, pp. 332-338 Jama : Journal of the American Medical Association, 326, 332-338 |
| ISSN: | 0098-7484 |
| DOI: | 10.1001/jama.2021.9889 |
| Popis: | Contains fulltext : 238007.pdf (Publisher’s version ) (Closed access) IMPORTANCE: Cases of cerebral venous sinus thrombosis in combination with thrombocytopenia have recently been reported within 4 to 28 days of vaccination with the ChAdOx1 nCov-19 (AstraZeneca/Oxford) and Ad.26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccines. An immune-mediated response associated with platelet factor 4/heparin antibodies has been proposed as the underlying pathomechanism. OBJECTIVE: To determine the frequencies of admission thrombocytopenia, heparin-induced thrombocytopenia, and presence of platelet factor 4/heparin antibodies in patients diagnosed with cerebral venous sinus thrombosis prior to the COVID-19 pandemic. DESIGN, SETTING, AND PARTICIPANTS: This was a descriptive analysis of a retrospective sample of consecutive patients diagnosed with cerebral venous sinus thrombosis between January 1987 and March 2018 from 7 hospitals participating in the International Cerebral Venous Sinus Thrombosis Consortium from Finland, the Netherlands, Switzerland, Sweden, Mexico, Iran, and Costa Rica. Of 952 patients, 865 with available baseline platelet count were included. In a subset of 93 patients, frozen plasma samples collected during a previous study between September 2009 and February 2016 were analyzed for the presence of platelet factor 4/heparin antibodies. EXPOSURES: Diagnosis of cerebral venous sinus thrombosis. MAIN OUTCOMES AND MEASURES: Frequencies of admission thrombocytopenia (platelet count 0.4, in a subset of patients with previously collected plasma samples). RESULTS: Of 865 patients (median age, 40 years [interquartile range, 29-53 years], 70% women), 73 (8.4%; 95% CI, 6.8%-10.5%) had thrombocytopenia, which was mild (100-149 ×103/μL) in 52 (6.0%), moderate (50-99 ×103/μL) in 17 (2.0%), and severe ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|